Cardiovascular News

Corcym has announced the first-in-human implantation of TriMemo, a semi-rigid annuloplasty ring dedicated to tricuspid valve repair. The procedure was performed at Cleveland Clinic (Cleveland, USA) by A Marc Gillinov, chairman of the Department of Thoracic and Cardiovascular Surgery and Judith Dion Pyle Chair in Heart Valve Research. In a press release, Corcym details that […] The post First-in-h…

Medtronic has received CE-mark approval for the Endurant stent graft system to remove a ruptured abdominal aortic aneurysm (rAAA) treatment warning, the company shared in a press release this week. The labelling update follows the US Food and Drug Administration (FDA) labelling approval received in October 2025. “When a patient presents with a ruptured abdominal […] The post Medtronic’s Endurant …

Elucid has raised US$55 million in an oversubscribed series D financing, with the funding to support the commercialisation of its artificial intelligence (AI)-powered cardiovascular imaging platform. The round brings Elucid’s total funding raised to date to approximately $185 million and includes new participation from a large medtech company, Elucid said in a press release. Proceeds […] The post…

Clopidogrel monotherapy was shown to be non-inferior to extended dual antiplatelet therapy (DAPT) with clopidogrel and aspirin for net adverse clinical events at 24 months among patients at high risk for ischaemic events after implantation of a drug-eluting stent, results of the A-CLOSE trial presented at the European Society of Cardiology (ESC) 2026 congress (28–31 […] The post ESC 2026: Clopido…

Routine concomitant closure of the left atrial appendage (LAA) during open-heart surgery should not be considered unless patients are high risk for stroke, results of the LAAACS-2 trial, presented at the European Society of Cardiology (ESC) 2026 congress (28–31 August, Munich, Germany), have shown. Surgical closure of the LAA is recommended in ESC Guidelines as […] The post ESC 2026: Trial result…

Use of the Envast (Vesalio) coronary clot retriever prior to percutaneous coronary intervention (PCI) has been shown to reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI) and large thrombus burden. Findings of the NATURE trial, a multicentre prospective randomised controlled trial assessing the safety and effectiveness of the stent-based thrombectomy technolog…

GE HealthCare has obtained a CE mark for Photonova Spectra—an advanced photon-counting computed tomography (CT) system featuring the company’s proprietary Deep Silicon detector technology. This regulatory milestone expands access and enables clinical adoption of the technology in countries that observe CE marking, as per a press release from GE HealthCare. “We are proud to deliver […] The post GE…

Late-breaking results from the FUSION trial, an investigator-initiated study using computed tomography (CT)-derived fractional flow reserve (FFR)—known as Heartflow FFRct (Heartflow)—for the diagnosis of patients with stable coronary artery disease (CAD), found that use of the artificial intelligence (AI)-derived technology reduced rates invasive coronary angiography by 44% compared to assessment…

GE HealthCare has achieved CE marking for Photonova Spectra, an advanced photon-counting computed tomography (PCCT) system with the company’s proprietary Deep Silicon detector technology. “We are proud to deliver this new generation of photon-counting CT to the clinicians and patients around the world it was intentionally designed to serve,” commented Chad Rowland, executive director, Global […] …

Medtronic has announced a strategic investment in Pi-Cardia, developer of ShortCut and other leaflet modification technologies for the treatment of heart valve disease. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve implantation (TAVI) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through the…

Protaryx Medical has announced the successful completion of the first US commercial cases using its US Food and Drug Administration (FDA)-cleared Protaryx transseptal puncture device. The procedures were performed at UC Davis Health in Sacramento, USA, by interventional cardiologist Gagan D Singh (University of California Davis Health, Sacramento, USA). The first two commercial cases were […] The…

A universal definition of myocardial infarction (MI) has been developed and published by four major cardiac societies: the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA) and the World Heart Federation (WHF). The Fifth Universal Definition of Myocardial Infarction will be presented at ESC’s annual congress this […] The post ESC …

HighLife SAS has announced CE mark approval for the HighLife Clarity mitral heart valve for use with the HighLife transcatheter mitral valve replacement (TMVR) system. The Clarity valve has been designed to further mitigate left ventricular outflow tract (LVOT) obstruction-related anatomical concerns while preserving HighLife’s transfemoral valve-in-ring architecture. The approval covers both Cla…

A new report from the UK advocacy charity Heart Valve Voice suggests that prompt diagnosis of heart valve disease and faster access to treatments such as transcatheter aortic valve implantation (TAVI) could reduce healthcare system costs through fewer emergency admissions, shorter hospital stays and less need for escalation to social services if patients remain in […] The post Heart Valve Voice h…

Tempus AI has announced it has received 510(k) clearance from the US Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an artificial intelligence (AI)-enabled software device that analyses standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ cardiovascular portfolio, expan…

Artificial intelligence (AI) models trained and validated in hospital-based populations to screen for structural heart disease are likely not to be effective in screening within the wider population due to differences in disease prevalence and phenotypes in the real world. This is according to a report from the PREVUE-VALVE study, a so-called “site-less” clinical trial […] The post Study highligh…

The American College of Cardiology (ACC) has announced the appointment of Mohamad Alkhouli (Mayo Clinic, Rochester, USA) as the new editor-in-chief of its interventional cardiology focused journal JACC: Cardiovascular Interventions. Alkhouli brings to the journal an internationally recognised career in interventional cardiology and cardiovascular research, along with more than a decade of editori…